ASX Share rice
Thu 13 Aug 2020 - 10:03:am (Sydney)

IVX Share Price

INVION LIMITEDIVXPharmaceuticals, Biotechnology & Life Sciences

IVX Company Information

Name:

Invion Limited

Sector:

Healthcare

Industry:

Drugs - Generic

GIC Industry:

Pharmaceuticals

GIC Sub Industry:

Pharmaceuticals

Address:

722 High Street Melbourne VIC Australia 3102

Phone:

61 3 9081 6005

Full Time Employees:

3

MD, CEO & Director:

Mr. Craig Newton

CFO & Company Sec.:

Ms. Melanie Jaye Leydin C.A., B.Bus, CA

Head of Intellectual Property Devel.:

Dr. Dean Naylor

Company Overview:

Invion Limited, a clinical-stage life-sciences company, develops photodynamic therapy for the treatment of various cancers in Australia. It develops IVX-P02 to treat skin cancers, as well as solid cancers, including lung, prostrate, and ovarian cancers; and IVX-MES, an intravenous treatment for mesothelioma. The company has a research and development alliance agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers; and partnership agreements with Formulytica and vivoPharm to develop and test IVX-P02 gel. Invion Limited also has a research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. The company is headquartered in Melbourne, Australia.

IVX Share Price Information

Shares Issued:

5.50B

Market Capitalisation:

$52.26M

Revenue (TTM):

$4.57M

Revenue Per Share (TTM):

$0

Profit Margin:

-0.2019

Operating Margin (TTM):

$-0.47

Return On Assets (TTM):

$-0.19

Return On Equity (TTM):

$-0.40

Quarterly Revenue Growth (YOY):

0.583

Gross Profit(TTM):

$1.63M

IVX CashFlow Statement

CashFlow Date:

2019-06-30

Investments:

$-13,608

Change To Liabilities:

$-1,147,792

Total Cashflow From Investing Activities:

$-13,608

Net Income:

$-1,064,098

Total Cash From Operating Activities:

$-2,105,693

Depreciation:

$309.57K

Change To Account Receivables:

$-1,458

Capital Expenditures:

$6.05K

IVX Income Statement

Income Date:

2019-06-30

Income Before Tax:

$-2,546,205

Net Income:

$-1,064,098

Gross Profit:

$3.88M

Operating Income:

$-2,517,382

Total Revenue:

$3.88M

Total Operating Expenses:

$6.40M

Cost Of Revenue:

$2.26M

IVX Balance Sheet

Balance Sheet Date:

2019-06-30

Intangible Assets:

$5.12M

Total Liabilities:

$604.71K

Total Stockholder Equity:

$5.46M

Other Current Liabilities:

$50.27K

Total Assets:

$6.06M

Common Stock:

$130.56M

Other Current Assets:

$50.27K

Retained Earnings:

$-148,218,009

Cash:

$771.31K

Total Current Liabilities:

$604.71K

Property - Plant & Equipment:

$4.82K

Net Tangible Assets:

$342.27K

Total Current Assets:

$0.94M

Net Receivables:

$28.81K

Short-Term Investments:

$5.12M

Accounts Payable:

$308.09K

Non Currrent Assets (Other):

$5.12M

Short-Term Investments:

$5.12

Non Current Liabilities Total:

$0

IVX Share Price History

IVX News

05 Dec, 2019
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...